Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

BACKGROUND: Immune checkpoint therapy (ICT) prolongs survival in subsets of patients with cancer but can also trigger immune-related adverse events (irAEs) requiring treatment discontinuation. Recent studies have investigated safety of ICT rechallenge after irAEs, and evidence suggests that rechalle...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Immunother Cancer
Prif Awduron: Siddiqui, Bilal A, Gheeya, Jinesh S, Goswamy, Rohit, Bathala, Tharakeswara K, Surasi, Devaki Shilpa, Gao, Jianjun, Shah, Amishi, Campbell, Matthew T, Msaouel, Pavlos, Goswami, Sangeeta, Wang, Jennifer, Zurita, Amado J, Jonasch, Eric, Corn, Paul G, Aparicio, Ana M, Siefker-Radtke, Arlene O, Sharma, Padmanee, Subudhi, Sumit K, Tannir, Nizar
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2021
Pynciau:
Clinical/Translational Cancer Immunotherapy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8323401/
https://ncbi.nlm.nih.gov/pubmed/34326169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002850
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg